​

Zymeworks (ZYME) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ZYME Stock Forecast

Zymeworks (ZYME) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $26.00, with a high of $26.00 and a low of $26.00. This represents a 40.77% increase from the last price of $18.47.

$5 $10 $15 $20 $25 $30 High: $26 Avg: $26 Low: $26 Last Closed Price: $18.47

ZYME Stock Rating

Zymeworks stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (84.21%), 3 Hold (15.79%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 3 16 Strong Sell Sell Hold Buy Strong Buy

ZYME Price Target Upside V Benchmarks

TypeNameUpside
StockZymeworks40.77%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts113
Avg Price Target$26.00$26.00$21.33
Last Closing Price$18.47$18.47$18.47
Upside/Downside40.77%40.77%15.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25172--10
Sep, 25172--10
Aug, 25172--10
Jul, 25172--10
Jun, 25172--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2025Robert BurnsH.C. Wainwright$26.00$18.1143.57%40.77%
Nov 21, 2024Andrew BerensLeerink Partners$26.00$13.6890.06%40.77%
Nov 01, 2024Derek ArchilaWells Fargo$12.00$13.28-9.64%-35.03%
Oct 28, 2024Stephen WilleyStifel Nicolaus$28.00$13.11113.58%51.60%
Sep 25, 2024Robert BurnsH.C. Wainwright$12.00$12.50-4.00%-35.03%
Sep 18, 2024Andrew BerensH.C. Wainwright$10.00$12.30-18.70%-45.86%
Sep 10, 2024Stephen WilleyStifel Nicolaus$21.00$11.7578.72%13.70%
Dec 19, 2022Akash TewariJefferies$11.00$6.7962.00%-40.44%
Nov 01, 2022Robert BurnsH.C. Wainwright$8.00$7.309.59%-56.69%
Sep 20, 2021Robert BurnsH.C. Wainwright$44.00$33.0733.05%138.22%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 27, 2025H.C. WainwrightBuyBuyhold
Oct 14, 2025H.C. WainwrightBuyBuyupgrade
Oct 10, 2025B. RileyBuyinitialise
May 20, 2025Cowen & Co.Buyinitialise
Mar 07, 2025CitigroupBuyBuyhold
Nov 21, 2024Leerink PartnersOutperformOutperformhold
Nov 07, 2024Leerink PartnersOutperformupgrade
Oct 22, 2024H.C. WainwrightBuyBuyhold
Oct 22, 2024H.C. WainwrightNeutralNeutralhold
Sep 18, 2024H.C. WainwrightNeutralNeutralhold

Financial Forecast

EPS Forecast

$-2K $-2K $-1K $-500 $0 $500 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.58$-4.06$1.91$-1.72$-1.62K----
Avg Forecast$-4.20$-4.55$-0.06$-1.96$-1.44$-1.75$-1.17$-1.91$-1.04
High Forecast$-1.37$-1.48$-0.03$-1.75$-1.30$-1.10$0.64$-0.98$-0.46
Low Forecast$-8.82$-9.56$-0.10$-2.29$-1.81$-2.20$-2.10$-3.06$-1.56
Surprise %-14.76%-10.77%-3283.33%-12.24%112238.19%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$38.95M$26.68M$412.48M$76.01M-----
Avg Forecast$33.86M$15.63M$240.59M$74.79M$89.49M$84.38M$160.95M$156.89M$196.94M
High Forecast$62.49M$28.84M$370.44M$81.28M$114.37M$112.26M$160.98M$217.23M$272.69M
Low Forecast$16.31M$7.52M$143.38M$71.60M$72.84M$49.90M$160.92M$89.68M$112.57M
Surprise %15.03%70.74%71.44%1.64%-----

Net Income Forecast

$-150B $-110B $-70B $-30B $10B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-180.55M$-211.84M$124.34M$-118.67M$-122.69B----
Avg Forecast$-114.30M$-254.98M$-280.48M$-118.67M$-113.67M$-116.02M$-69.54M$-166.65M$-71.62M
High Forecast$-91.44M$-203.99M$-224.39M$-94.94M$-89.37M$-75.99M$44.04M$-67.49M$-31.73M
Low Forecast$-137.16M$-305.98M$-336.58M$-142.41M$-124.36M$-151.24M$-144.71M$-210.72M$-107.42M
Surprise %57.97%-16.92%-144.33%-107838.70%----

ZYME Forecast FAQ

Is Zymeworks stock a buy?

Zymeworks stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Zymeworks is a favorable investment for most analysts.

What is Zymeworks's price target?

Zymeworks's price target, set by 19 Wall Street analysts, averages $26 over the next 12 months. The price target range spans from $26 at the low end to $26 at the high end, suggesting a potential 40.77% change from the previous closing price of $18.47.

How does Zymeworks stock forecast compare to its benchmarks?

Zymeworks's stock forecast shows a 40.77% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Zymeworks over the past three months?

  • October 2025: 10.00% Strong Buy, 70.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 10.00% Strong Buy, 70.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 10.00% Strong Buy, 70.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Zymeworks’s EPS forecast?

Zymeworks's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.75, marking a -99.89% decrease from the reported $-1.618K in 2024. Estimates for the following years are $-1.17 in 2026, $-1.91 in 2027, and $-1.04 in 2028.

What is Zymeworks’s revenue forecast?

Zymeworks's average annual revenue forecast for its fiscal year ending in December 2025 is $84.38M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $160.95M, followed by $156.89M for 2027, and $196.94M for 2028.

What is Zymeworks’s net income forecast?

Zymeworks's net income forecast for the fiscal year ending in December 2025 stands at $-116M, representing a -99.91% decrease from the reported $-123B in 2024. Projections indicate $-69.542M in 2026, $-167M in 2027, and $-71.618M in 2028.